The document summarizes a presentation on developing paclitaxel nanoparticles using human serum albumin (HSA) as a polymer. Paclitaxel is insoluble in water and has low bioavailability. Nanoparticles can increase paclitaxel's stability, target delivery to tumor sites, and reduce toxicity. The method involves dissolving paclitaxel in chloroform and mixing it with an HSA solution to form an emulsion. The chloroform is then evaporated to form paclitaxel-loaded HSA nanoparticles.